AlphAIalphai — Financial news for AI agents
Investing.comMAY 53 min read$VNRX

H.C. Wainwright cuts VolitionRX stock price target to $1 on share count

H.C. Wainwright has reduced its price target for VolitionRx (NYSE:VNRX) to $1.00 from $1.50, citing an increased share count, while maintaining a Buy rating. The company reported a Q4 2025 revenue miss, coming in at $0.4 million against a projected $0.8 million, and a net loss of $6.3 million. Despite a weak financial health score and cash burn, InvestingPro's Fair Value analysis suggests the stock might be undervalued.

Original reporting
Investing.com · Investing.com
Published May 5, 2026, 6:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 5, 2026, 6:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count — source image
Source · Investing.com
Decision brief

The 30-second read

$VNRXBearishMed
01

Why it matters

The downgrade and revenue miss could pressure the stock further, especially if broader biotech sentiment remains negative.

02

Market read

The news is highly relevant for traders holding or considering VNRX, with potential short-term downside risk.

03

What to watch

Possible upcoming catalysts such as pipeline developments or strategic partnerships could offset current negative sentiment.

Timing: Immediate, as the news is recent and impacts current trading session.

Background

VolitionRx reported a revenue miss in Q4 2025, with increased share count diluting existing shareholders, leading to analyst downgrades.

Company-level read

Ticker impact

$VNRXBearishMedium confidence
Context

The news directly pertains to VolitionRx (VNRX), affecting its stock outlook.

Expected impact

Moderate decline expected in the short term, with potential for continued weakness if financial results deteriorate further.

Evidence & confidence

The price target cut and revenue miss signal short-term weakness; however, the maintained Buy rating and undervaluation analysis suggest possible long-term value.

Market effects

Sector

The life sciences sector may experience slight negative sentiment due to financial underperformance of a biotech company.

Regional

Limited regional impact; primarily affects US biotech stocks.

Global

Low; specific to VNRX and related biotech sector.

Counterpoint

What could challenge this read

The stock may be oversold, and the undervaluation suggests a potential rebound if the company improves financial performance or if the market overreacts.

Key entities

  • Analyst Firm
    H.C. Wainwright

    Investment bank and research firm providing the price target.

  • Company
    VolitionRx

    Biotech company specializing in cancer detection.

Read at source← All news

Related articles

AUG 8
$NVDAMed

Nvidia to Invest Up to $3 Billion in Blackstone

The Information reported Nvidia plans to invest up to $3 billion in Lancium, a Blackstone-backed power and data center infrastructure developer tied to the Stargate AI initiative. Nvidia would initially put in $2 billion for a 20% stake, with up to $1 billion more contingent on performance thresholds. No company comment was provided.

econotimes.com4 min
AUG 8
$NVDAMed

Nvidia to invest up to US$3 billion in Stargate data centre developer Lancium: The Information

Nvidia plans to invest up to $3 billion in Lancium, the developer of the Stargate data center campus in Texas, The Information reported. Nvidia would invest $2 billion for about a 20% stake, with an additional $1 billion possible based on grid hookup thresholds. Lancium’s land and power portfolio has an enterprise value near $10 billion, and it may explore an IPO in 2027.

businesstimes.com.sg4 min
AUG 8
$USARMed

Is USA Rare Earth (USAR) Overvalued On Its DOE Funding And Tokenization Buzz?

Simply Wall St says USA Rare Earth (USAR) shares have rebounded after being selected by the U.S. Department of Energy for up to $19.3M in federal funding, pending final negotiations, for a pilot-scale rare earth separations project. The article cites mixed valuation views, with a “fair value” of $0.33 versus a DCF estimate of $83.09, and notes recent price returns.

simplywall.st6 min
AUG 8
$000660.KSMed

SK Hynix mulling options for US$3 bil Chongqing plant — Bloomberg

Bloomberg reports SK Hynix is exploring options for its Chongqing, China semiconductor packaging and testing plant, including possibly bringing in an investor. A potential stake sale could value the facility at about US$3 billion, according to people familiar. Separately, SK Hynix plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND, citing AI-driven demand.

theedgemalaysia.com4 min
AUG 8
$OESXMed

Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting

Orion Energy Systems (NASDAQ:OESX) reported FY2026 revenue targets of $95M to $97M and expects positive adjusted EBITDA for the year, after margin gains at its annual meeting. LED lighting revenue rose to $55.9M from $47.7M, with gross margin up to 33.8%. EV charging revenue fell to $14.4M from $16.8M, while maintenance revenue rose to $16.0M.

yahoo.com4 min